English (UK)
中文版Yong H. Park
- Focused on developing PD1+ peripheral blood-derived, tumor-reactive CD8+ T cell (PBTL) therapies as a platform for the treatment of solid tumors that are rare, orphan, and have critical (high) unmet need
- PBTL is a simpler, smarter version of TIL
- PBTL is a process to select highly tumor-reactive T cells from a patient's peripheral blood based on the expression of two specific T cell surface markers: PD-1 and/or TIM-3
- After selection, expanded to large quantities, it gets re-infused into the patient via the ACT regimen
- PBTL technology has been patented (issued) already in the US, China, the EU, Japan, Australia
- MEDGENE has robust Clinical Development Pipelines (currently, 9 as monotherapy way)
- Looking for funding for entering Phase I/2 in three pipelines in the US
- Looking for partnering for the Asian market (China, Japan, South Korea)
MedGene Therapeutics
CEOMiss Heidi Pavliska
Pavliska Industries
Senior Director Business DevelopmentJasper Pei
Xuanzhu Biopharmaceutical
BD managerDr. Xiaoxiao Peng
Efung Capital
Partner
Mrs. Lilian Peng
Jemincare is a leading pharmaceutical group in China with $5.2B revenue in 2019. JeminCare is dedicated to providing novel healthcare solutions with Rx and OTC drugs with strategic fields in renal disease, oncology, cardiovascular, anti-infection, respiratory, and analgesic. We have a well-established marketing and sales network in China with a team of more than 5000 sales reps.
Located in Shanghai, Jemincare R&D center has 400+ experienced scientists and more than 30 novel prescription drugs in the pipeline.
Jemincare
BD ManagerZhao Peng
3SBio is a fully-integrated biotechnology company in China with commercial and R&D programs in oncology, auto-immune diseases, nephrology, metabolic diseases and dermatology, and seeking in-licensing opportunity of novel therapies and technologies.
3SBio is actively pursuing international expansion through acquisitions, licensing and strategic partnerships. Please visit www.3sbio.com for more information.
We look forward to having opportunity to discuss potential collaboration with you.
3S Pharmaceutical Group
Senior BD ManagerMr. Leo Petrilli
Virtual meetings Host, Guest, Panelist, Master of Ceremonies.
Absenteeism. Presenteeism.
Addiction Recovery Coach AND MentorMr. David Platt
Academic study on a small number of patients with the first drug candidate had positive results. The viral load was reduced to zero in all mild/moderate patient after a few days. The drug is not toxic and had no adverse effects. It can prevent spread of infection in 24 hours. It is complementary to vaccination and can prevent infection from close contact. Next step is stage III trials for a bigger group of patients.
We are looking for investors to fund our next phase.
Bioxytran/Pharmalectin
CEODr. Steven Potts
OncoMyx Therapeutics is developing potentially best-in-class (multi-armed, IV/systemically-delivered, precision medicine) oncolytic immunotherapies based upon the myxoma virus (MYXV) platform, and we have demonstrated mechanism of action and combinatorial efficacy (tumor growth inhibition) when dosed IV with various checkpoint inhibitors in multiple animal models. Our company has the industry’s most experienced oncolytic virus (OV) development team and an experienced SAB, and CEO Steve Potts was previously an executive at Ignyta (acquired by Roche for $1.7B). OncoMyx raised a $25M series A in June 2019 to advance our lead preclinical program to IND, and among our investors are BIVF (exited OV investment ViraTx for $244M at preclinical stage in 2018) and Jonathan Lim (Ignyta CEO & current Erasca CEO). On the heels of presenting our preclinical data at SITC and announcing the appointment of Mirati CEO Chuck Baum as our new Chairperson, OncoMyx is seeking a $50M+ series B/crossover to prepare for an IPO and focus on a future transition into a clinical-stage organization. Pasted below are links to our SITC posters and some recent Fierce and BioSpace articles focused on our company.
https://www.oncomyx.com/oncomyx-announces-presentation-of-preclinical-efficacy-data-of-novel-oncolytic-immunotherapy-at-sitc-2020/
https://www.fiercebiotech.com/research/arming-rabbit-pox-virus-to-fight-cancer
https://www.biospace.com/article/oncomyx-s-oncolytic-virus-platform-shows-preclinical-efficacy-boosting-immunotherapy-potential/
OncoMyx Therapeutics
Cofounder, CEO & DirectorFelicia Pullam
- As one of the nation’s largest and fastest growing biotechnology clusters, Maryland is #1 in Ph.D. concentration in biological fields, employed doctoral scientists, and was recognized last year at the 4th best biotechnology cluster in the nation by Genetic Engineering and Biotechnology News.
- We have facilitated access to 74 Federal laboratories, including the National Institutes of Health, the National Institute for Standards and Technology, the Food and Drug Administration, and the Walter Reed Army Institute of Research.
- We can reach 80% of the U.S. pharmaceutical industry and four nearby international airports to enable efficient travel.
- Maryland’s Cost of Doing Business Index is 16%, 12%, and 10% lower than in Boston, New Jersey, and California, respectively, according to Moody’s Analytics Regional Financial Review. In our industry, that translates to a lower cost of operations and wet lab space.
- The cost of living in Maryland can be up to one-and-a-half times lower than in the metropolitan areas of New York, Boston, and San Francisco, according to the Council for Community and Economic Research.
Responsive Web Design powered by 